bldbnkr

Agree with Kelly
 

Nope.  Positive is positive.
 

An EXCELLENT question Darren ! I look forward to some interesting debate.

NO!
I am a professional blood group sereologist!

It definitely should be a part of the medical record, electronic or otherwise.
No need for BB to keep the document - medical record.  I'd put a note on the patient record card/BBIS for future reference.

I do as David does - a note to indicate that the patient is a Jehovah's Witness. If the patient has accepted plasma but not red cells, I will also note that. Saves them a bill for an unwanted crossmatch sometimes if I can notify the provider that he/she should discuss transfusion with the patient before we perform testing to set up red cells for them. (And yes, I think that providers should discuss transfusion with their patients, ideally before ordering the products, but we know that the real world doesn't always work that way.)

I'm afraid that I have to disagree.  bbguy.org is not good - IT IS BRILLIANT!

Dosage addresses the expression of ag on the red cell.and its reactivity with antibody.  Homozygous intimates a single expression of the gene.  Let's say we/re talkijng about the K ag.  KK is homozygous for K, Kk is heterozygous for both K and k , kk ia homozygous for k.  Dosage occurs when the antibody reacts less strong when the gene products are heterozygous, i.e, the homozygous expression will display stronger reactions.  
The systems which express dosage are the Rh, MNSs, Kidd, and Duffy.  The texts tell you the Kell system ags do not express dosage but I have found the reality is that they do.
When ruling out antibodies it is generally considered good practice to not rule out based on a negative result with a heterozygous cell. There are modalities of testing which enable the use of heterozygous cells for rule outs:  enzyme pretreatment (not for Duffy or MNSs);  I've also considered PeG to be valid for this.  
Hope this helps
 

FDA inspectors have told me that they have jurisdiction over all transfusion services.  They just choose to restrict themselves to sites that perform certain modifications (e.g. washing and/or irradiating).

Yes. I missed that part about it being crossmatch incomplatible to other normal donors. 
I would definitely return the unit to the supplier.

I would pull the unit from inventory and contact the supplier. They should have the resources to investigate the problem with the donor.

Sorry, that was a very old post, those tools are no longer available.

"Compatible blood for a corpse is not a triumph" 
(sorry - forgot who to attribute this to)

You have NEVER seen a baby who is Weak D Positive.
There is no such thing as anti-Weak D!  May I suggest that you read Stratton F.  A new Rh allelomorph.  Nature 1946; 158: 25-26, followed closely by Race RR, Sanger R, Lawler SD.  The Rh antigen Du. Ann Eugen (Camb) 1948; 14: 171-184, which will explain why there is no such thing as anti-Weak D.

I appreciate that CAP seem to be incapable of using correct terminology, but that does not mean that we should all descend to their levels of incompetence.
Sorry for the "vent", but this wrong terminology has gone on now for 72 years; six years more (embarrassingly) than I have been alive!
I'm sorry if this sounds like a personal RANT against you. YorkshireExile; it is certainly not meant as such.  It is just a general rant against people who use poor nomenclature because they don't learn even the basic history of their own specialist subject - and that includes the people who SUPPOSEDLY make sure the rest of us "follow the rules"!

I have an SOP for Convalescent Plasma. It closely follows the Mayo study protocol and guidelines as that is how we are administering the product.

And just to add a bit to what Scott said, I will give an example.
There are, on average 14, 000 Kidd antigens per red cell.
This means that for a red cell with the phenotype Jk(a+b-), with a probable genotype of JKA/JKA, all 14, 000 Kidd antigens would be Jka.  Similarly,in the case of Jk(a-b+), with a probable genotype of JKB/JKB, all 14, 000 Kidd antigens would be Jkb.
In the case of a red cell with the phenotype Jk(a+b+), with a probable genotype of JKA/JKB, 7, 000 of the Kidd antigens would be Jka, and 7, 000 of the Kidd antigens would be Jkb.
In the case of a weakly reacting anti-Jka, showing dosage, the antibody would react with the Jk(a+b-) red cells, but would not necessarily react (visually) at all with the Jk(a+b+) red cells - or may react with them, but the reactions would be distinctly weaker than the reactions with the Jk(a+b-) red cells.
In the case of a weakly reacting anti-Jkb showing dosage, the antibody would react with the Jk(a-b+) red cells, but would not necessarily react (visually) at all with the Jk(a+b+) red cells - or may react with them, but the reactions would be distinctly weaker than the reactions with the Jk(a-b+) red cells.
I hope this helps, and doesn't serve to muddy the waters more.

No, I meant ABO identical. Giving A plasma to O patients is not a good idea, despite 100 years of practice, give or take.  A plasma contains soluble A antigen glycolipids and glycoproteins, and these interact with the anti-A in the group O recipient, forming huge immune complexes.  We and others have observed that patients receiving "compatible plasma" have increased bleeding, increased lung injury and increased risks of infection.  The studies that suggest this isn't true are fatally flawed by characterizing the patients receiving platelets or plasma by their first transfusion (ABO identical or not), regardless of what subsequent transfusions they received. Stick with ABO identical if at all possible.

We have all codes in safetrace. 
1) anyone has thought about billing code?
2) also order service table: this will be same as FFP, right?

I think ICCBBA may release some information on 1 April.  They are, of course, operating under the same sort of constraints as the rest of us.

I asked the blood bank manager and director if I need to put these codes in our computer system; I have not heard back from them.
 

Blood shortages are a big problem in parts of the US. Donors are not presenting, drives are being cancelled. Those patients who normally need blood products will be affected by that. I can't speak to Covid19 patients specifically...yet. We have been asked to reduce our stock by 25% and cut usage by 25% so that blood products will be available for those who need it most.

I just got a memo from the ARC. They are working on convalescent plasma supplies. No details yet.

Sonya Martinez,
Where are you going to get the COVID-19 convalescent plasma?  I had a physician inquire about that this morning.  I don't think our normal providers will have that as it is still considered "experimental."  
Thanks!

I believe that once ventilated, due to the risk of DIC, some COVID19 patients are requiring extensive platelet support. Thank fully not seeing this at present in Scotland, however numbers of patients testing positive are increasing daily.
 

Really sick patients needing ECMO will use blood. I don’t have a way to gauge the utilization at this time though. 
All the best.